Apyx Medical Corporation (APYX)
| Market Cap | 199.53M +256.9% |
| Revenue (ttm) | 55.90M +18.2% |
| Net Income | -9.17M |
| EPS | -0.22 |
| Shares Out | 41.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 207,575 |
| Open | 4.650 |
| Previous Close | 4.470 |
| Day's Range | 4.630 - 4.990 |
| 52-Week Range | 1.590 - 4.990 |
| Beta | 1.39 |
| Analysts | Strong Buy |
| Price Target | 6.50 (+36.27%) |
| Earnings Date | May 7, 2026 |
About APYX
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparo... [Read more]
Financial Performance
In 2025, Apyx Medical's revenue was $52.84 million, an increase of 9.86% compared to the previous year's $48.10 million. Losses were -$11.21 million, -52.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for APYX stock is "Strong Buy." The 12-month stock price target is $6.5, which is an increase of 36.27% from the latest price.
News
Apyx Medical Slides: Investor presentation
Apyx Medical has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway
CLEARWATER, Fla., May 27, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON B...
New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®
Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach Published data demonstrates visible reduction in dimpling and progressive ...
Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction
CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AY...
Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™
Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON Addition of the power liposuction capability as a second...
Apyx Medical reports Q1 EPS (5c), consensus (11c)
Reports Q1 revenue $12.49M, consensus $10.77M. “Our first quarter results reflect continued execution against our commercial strategy, with strong revenue growth driven by adoption of AYON in the U.S....
Apyx Medical raises FY26 revenue view to $59M-$60M from $57.5M-$58.5M
Consensus $57.84M. Backs FY26 operating expenses view less than $45M.
Apyx Medical Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 32% year-over-year to $12.5M, led by AYON system sales and strong international demand. Gross margin improved to 63.5%, and full-year guidance was raised to $59–$60M. AYON adoption is early, with FDA clearance for power liposuction expected soon.
Apyx Medical Earnings release: Q1 2026
Apyx Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Apyx Medical Quarterly report: Q1 2026
Apyx Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.
Apyx Medical Corporation Reports First Quarter 2026 Financial Results
CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON...
Weight-loss revolution sparks new appetite for aesthetics firms
Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quart...
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the ...
Renuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"
Renuvion continues to lead in minimally invasive body contouring as the trusted solution for loose skin. CLEARWATER, Fla.
Apyx Medical price target raised to $6 from $5 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Apyx Medical (APYX) to $6 from $5 and keeps a Buy rating on the shares. The firm notes the company reported a strong…
Apyx Medical Transcript: The Citizens Life Sciences Conference 2026
AYON, a fully integrated surgical aesthetics system, is driving strong growth and market interest by consolidating multiple technologies and addressing new demand from GLP-1-induced skin laxity. The company is achieving operational efficiencies, expanding internationally, and expects 17%-19% revenue growth this year.
Apyx Medical upgraded to Buy from Neutral at BTIG
BTIG analyst Sam Eiber upgraded Apyx Medical (APYX) to Buy from Neutral with a $6 price target The firm cites positive early momentum with the Ayon launch, growing demand for…
Apyx Medical Earnings Call Transcript: Q4 2025
Record Q4 revenue and strong AYON system adoption drove 35% year-over-year growth, with positive EBITDA and improved cash flow. 2026 guidance projects continued double-digit growth in surgical aesthetics, with plans for international expansion and further product enhancements.
Apyx Medical Annual report: Q4 2025
Apyx Medical has published its Q4 2025 annual report on March 10, 2026.
Apyx Medical Earnings release: Q4 2025
Apyx Medical released its Q4 2025 earnings on March 10, 2026, summarizing the period's financial results.
Apyx Medical sees FY26 revenue $57.5M-$58.5M, consensus $56.05M
Total revenue in the range of $57.5 million to $58.5 million. This is compared with $52.8 million reported for the year ended December 31, 2025. The Company expects operating expenses…
Apyx Medical reports Q4 EPS (3c), consensus (6c)
Reports Q4 revenue $19.16M, consensus $19.12M. “We are making steady progress scaling the U.S. commercial program for AYON following its official launch in September 2025, with early customer interest...
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AY...
Apyx Medical Corporation to Participate in The Citizens Life Sciences Conference
CLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the A...
Apyx Medical reports preliminary Q4 revenue $19M-$19.2M, consensus $17.47M
“We are excited by AYON’s commercial launch, which delivered immediate momentum and contributed to a strong fourth quarter, including an increase of approximately 51% in revenue for our Surgical Aesth...